WO2023285334 - NOVEL FATTY ACID MODIFIED UROCORTIN 2 DERIVATIVES AND THE USES THEREOF
National phase entry is expected:
Publication Number
WO/2023/285334
Publication Date
19.01.2023
International Application No.
PCT/EP2022/069225
International Filing Date
11.07.2022
Title **
[English]
NOVEL FATTY ACID MODIFIED UROCORTIN 2 DERIVATIVES AND THE USES THEREOF
[French]
NOUVEAUX DÉRIVÉS D'UROCORTINE 2 MODIFIÉS PAR UN ACIDE GRAS ET LEURS UTILISATIONS
Applicants **
NOVO NORDISK A/S
Novo Allé
2880 Bagsværd, DK
Inventors
LI, Chien
Novo Nordisk Research Centre 530 Fairview Ave N
Seattle, Washington 98109, US
COX, Nicholas Raymond
Novo Nordisk Research Centre 530 Fairview Ave N
Seattle, Washington 98109, US
O'NEILL, Jason
Novo Nordisk Research Centre 530 Fairview Ave N
Seattle, Washington 98109, US
GARIBAY, Patrick William
Novo Allé
2880 Bagsværd, DK
CHRISTOFFERSEN, Berit Østergaard
Novo Allé
2880 Bagsværd, DK
ÅSBERG, Hans Dennis
Novo Allé
2880 Bagsværd, DK
LYKKE, Lennart
Novo Allé
2880 Bagsværd, DK
ROED, Nikolaj Kulahin
Novo Allé
2880 Bagsværd, DK
Priority Data
63/220,788
12.07.2021
US
21201010.2
05.10.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1403 | |
| EPO | Filing, Examination | 5277 | |
| Japan | Filing | 596 | |
| South Korea | Filing | 608 | |
| USA | Filing, Examination | 2710 |
Total: 10594 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Ucn2 derivatives comprising a peptide and a substituent with high potency, high physical and high chemical stability, suitable for administration to humans, and their medical use in treatment and/or prevention of obesity and/or diabetes.[French]
L'invention concerne des dérivés d'Ucn2 comprenant un peptide et un substituant ayant une puissance élevée, une stabilité physique élevée et une stabilité chimique élevée, appropriés pour être administrés à des êtres humains, et leur utilisation médicale dans le traitement et/ou la prévention de l'obésité et/ou du diabète.